266 Views
Sunday Poster Session
Category: Esophagus
Nabil El Hage Chehade, MD
MetroHealth Medical Center
Cleveland, OH, United States
Outcome | Subgroups | Included studies | OR & 95% CI P-value | P-value | I2 |
Complete Histologic Remission | 10 | 44.75 [20.45, 97.93] | < 0.00001 | 11% | |
Mode of Delivery | Spray | 3 | 25.12 [5.46, 115.62] | < 0.0001 | 0% |
Oral Suspension | 6 | 38.71 [14.84, 100.94] | < 0.00001 | 8% | |
Orodispersible Tablet | 1 | 236.73 [31.54, 1776.93] | 0.00001 | NA | |
Type | Fluticasone | 3 | 25.12 [5.46, 115,62] | 0.0001 | 0% |
Budesonide | 7 | 55.24 [20.54, 148.53] | 0.00001 | 26% | |
Partial Histologic Remission | 10 | 30.80 [9.98, 95.06] | 0.00001 | 74% | |
Endoscopic Remission | 6 | 8.28 [2.83, 24.22] | 0.0001 | 63% | |
Clinical Remission | 9 | 3.02 [1.41, 6.47] | 0.005 | 79% | |
Oroesophageal Candidiasis | 6 | 5.31 [1.94, 14.52] | 0.001 | 0% |